Telix Pharmaceuticals Limited (TLX) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
54.82
-7% vs avg
5yr avg: 59.07
30Y Low59.1·High59.1
P/FCF
172.19
-7% vs avg
5yr avg: 185.18
30Y Low185.2·High185.2
P/B Ratio
8.97
-4% vs avg
5yr avg: 9.36
30Y Low9.4·High9.4
ROE
↑
13.9%
↓+114% vs avg
5yr avg: -98.7%
30Y Low-253%·High14%
Debt/EBITDA
↑
6.62
↑+91% vs avg
5yr avg: 3.46
30Y Low0.3·High6.6
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
TLX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Telix Pharmaceuticals Limited trades at 105.5x earnings, roughly in line with its 5-year average of 110.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.3x, the stock trades at a premium of 372%. On a free-cash-flow basis, the stock trades at 172.2x P/FCF, 7% below the 5-year average of 185.2x.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $3.6B | $5.3B | — | — | — | — | — | — | — |
| Enterprise Value | $3.5B | $5.2B | — | — | — | — | — | — | — |
| P/E Ratio → | 105.48 | 110.00 | — | — | — | — | — | — | — |
| P/S Ratio | 6.31 | 6.79 | — | — | — | — | — | — | — |
| P/B Ratio | 8.97 | 9.36 | — | — | — | — | — | — | — |
| P/FCF | 172.19 | 185.18 | — | — | — | — | — | — | — |
| P/OCF | 114.87 | 123.54 | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
TLX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
Telix Pharmaceuticals Limited's enterprise value stands at 54.8x EBITDA, 7% below its 5-year average of 59.1x. The Healthcare sector median is 14.4x, placing the stock at a 281% premium on an enterprise-value basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 6.62 | — | — | — | — | — | — | — |
| EV / EBITDA | 54.82 | 59.07 | — | — | — | — | — | — | — |
| EV / EBIT | 58.62 | 56.05 | — | — | — | — | — | — | — |
| EV / FCF | — | 180.69 | — | — | — | — | — | — | — |
TLX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Telix Pharmaceuticals Limited earns an operating margin of 10.5%. Operating margins have expanded from -57.4% to 10.5% over the past 3 years, signaling improving operational efficiency. ROE of 13.9% is modest. ROIC of 25.5% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 65.1% | 65.1% | 62.6% | 18.3% | -391.9% | -323.7% | -340.7% | 100.0% | — |
| Operating Margin | 10.5% | 10.5% | 10.3% | -57.4% | -1069.6% | -944.8% | -1155.1% | -8037.7% | — |
| Net Profit Margin | 6.4% | 6.4% | 1.0% | -65.0% | -1059.9% | -861.1% | -799.6% | -7087.1% | — |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | 13.9% | 13.9% | 4.6% | -253.3% | -198.4% | -60.2% | -45.3% | -27.1% | -12.9% |
| ROA | 5.2% | 5.2% | 1.6% | -56.2% | -60.2% | -34.5% | -31.1% | -21.6% | -12.5% |
| ROIC | 25.5% | 25.5% | 451.4% | — | — | -239.2% | -106.9% | -79.1% | -543.2% |
| ROCE | 11.5% | 11.5% | 24.9% | -74.5% | -77.5% | -42.9% | -50.2% | -26.6% | -12.8% |
TLX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Telix Pharmaceuticals Limited carries a Debt/EBITDA ratio of 6.6x, which is highly leveraged (101% above the sector average of 3.3x). The company holds a net cash position — cash of $710M exceeds total debt of $581M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns. Interest coverage of 3.8x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.02 | 1.02 | 0.12 | 0.13 | 1.18 | 0.03 | 0.03 | 0.03 | 0.01 |
| Debt / EBITDA | 6.62 | 6.62 | 0.30 | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.23 | -0.71 | -1.32 | -9.04 | -0.96 | -0.61 | -0.45 | -0.98 |
| Net Debt / EBITDA | -1.47 | -1.47 | -1.80 | — | — | — | — | — | — |
| Debt / FCF | — | -4.49 | -7.45 | — | — | -44.24 | — | — | — |
| Interest Coverage | 3.83 | 3.83 | 3.83 | -226.43 | -429.88 | -41.92 | -16.72 | -540.52 | -677.34 |
Net cash position: cash ($710M) exceeds total debt ($581M)
TLX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Telix Pharmaceuticals Limited's current ratio of 2.78x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 2.02x to 2.78x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.78 | 2.78 | 1.43 | 2.02 | 1.25 | 4.69 | 5.52 | 4.35 | 33.74 |
| Quick Ratio | 2.66 | 2.66 | 1.32 | 1.96 | 1.16 | 4.66 | 5.47 | 4.27 | 33.54 |
| Cash Ratio | 2.15 | 2.15 | 0.78 | 1.36 | 0.58 | 3.91 | 4.20 | 3.13 | 33.20 |
| Asset Turnover | — | 0.52 | 1.26 | 0.61 | 0.07 | 0.03 | 0.03 | 0.00 | — |
| Inventory Turnover | 7.17 | 7.17 | 10.87 | 22.67 | 10.82 | 34.90 | 28.34 | — | 0.01 |
| Days Sales Outstanding | — | 74.10 | 57.77 | 71.00 | 1001.64 | 993.62 | 1362.49 | 16778.73 | — |
TLX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Telix Pharmaceuticals Limited does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 0.9% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 0.9% | 0.9% | — | — | — | — | — | — | — |
| FCF Yield | 0.6% | 0.5% | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — | — | — | — |
| Shares Outstanding | — | $345M | $324M | $311M | $282M | $257M | $233M | $202M | $128M |
Peer Comparison
Compare TLX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 TLXYou | $4B | 105.5 | 54.8 | 172.2 | 65.1% | 10.5% | 13.9% | 25.5% | 6.6 |
 EXEL | $12B | 16.6 | 12.7 | 13.9 | 96.4% | 37.6% | 35.5% | 32.1% | 0.2 |
 RNW | $1B | 46.7 | 11.3 | — | 91.1% | 53.5% | 3.0% | 4.9% | 10.1 |
 AGEN | $132M | -1102.9 | — | — | 90.3% | -18.0% | — | — | — |
 LNTH | $6B | 26.7 | 14.6 | 16.7 | 61.1% | 20.2% | 21.4% | 30.6% | 0.0 |
 NVS | $277B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 BMY | $115B | 16.3 | 9.2 | 8.9 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 GE | $316B | 37.1 | 32.5 | 43.5 | 36.8% | 19.1% | 45.3% | 24.7% | 2.1 |
 GEHC | $28B | 13.5 | 10.0 | 18.5 | 40.0% | 13.4% | 21.6% | 13.3% | 3.0 |
 SYK | $113B | 35.0 | 20.3 | 26.3 | 64.0% | 19.5% | 15.1% | 11.4% | 2.4 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See TLX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TLX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TLX vs EXEL
Side-by-side business, growth, and profitability comparison vs Exelixis, Inc..
Start ComparisonTLX — Frequently Asked Questions
Quick answers to the most common questions about buying TLX stock.
What is Telix Pharmaceuticals Limited's P/E ratio?
Telix Pharmaceuticals Limited's current P/E ratio is 105.5x. The historical average is 110.0x.
What is Telix Pharmaceuticals Limited's EV/EBITDA?
Telix Pharmaceuticals Limited's current EV/EBITDA is 54.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 59.1x.
What is Telix Pharmaceuticals Limited's ROE?
Telix Pharmaceuticals Limited's return on equity (ROE) is 13.9%. The historical average is -72.3%.
Is TLX stock overvalued?
Based on historical data, Telix Pharmaceuticals Limited is trading at a P/E of 105.5x. Compare with industry peers and growth rates for a complete picture.
What are Telix Pharmaceuticals Limited's profit margins?
Telix Pharmaceuticals Limited has 65.1% gross margin and 10.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does Telix Pharmaceuticals Limited have?
Telix Pharmaceuticals Limited's Debt/EBITDA ratio is 6.6x, indicating high leverage. A ratio above 4x may signal elevated financial risk.